Taysha Gene Therapies Book Value Per Share Growth & History (TSHA)
Taysha Gene Therapies's book value per share was $0.87 for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.87 | $0.52 | +148.22% |
| 2024 | 2024-12-31 | $0.35 | -$0.05 | −12.93% |
| 2023 | 2023-12-31 | $0.40 | $0.39 | +2569.62% |
| 2022 | 2022-12-31 | $0.02 | -$2.46 | −99.39% |
| 2021 | 2021-12-31 | $2.48 | -$4.18 | −62.75% |
| 2020 | 2020-12-31 | $6.65 | — | — |
Taysha Gene Therapies quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.19 | $0.28 | +30.54% |
| Q1 2026 | 2026-03-31 | $0.74 | $0.47 | +174.77% |
| Q4 2025 | 2025-12-31 | $0.87 | $0.52 | +148.22% |
| Q3 2025 | 2025-09-30 | $0.80 | $0.37 | +84.52% |
| Q2 2025 | 2025-06-30 | $0.91 | $0.37 | +68.70% |
| Q1 2025 | 2025-03-31 | $0.27 | -$0.02 | −6.75% |
| Q4 2024 | 2024-12-31 | $0.35 | -$0.05 | −12.93% |
| Q3 2024 | 2024-09-30 | $0.43 | $0.70 | — |
| Q2 2024 | 2024-06-30 | $0.54 | $1.12 | — |
| Q1 2024 | 2024-03-31 | $0.29 | $0.52 | — |
| Q4 2023 | 2023-12-31 | $0.40 | $0.39 | +2569.62% |
| Q3 2023 | 2023-09-30 | -$0.26 | -$0.52 | — |
| Q2 2023 | 2023-06-30 | -$0.58 | -$1.37 | — |
| Q1 2023 | 2023-03-31 | -$0.24 | -$1.55 | — |
| Q4 2022 | 2022-12-31 | $0.02 | -$2.46 | −99.39% |
| Q3 2022 | 2022-09-30 | $0.26 | -$3.39 | −92.88% |
| Q2 2022 | 2022-06-30 | $0.79 | -$4.07 | −83.69% |
| Q1 2022 | 2022-03-31 | $1.32 | -$4.58 | −77.65% |
| Q4 2021 | 2021-12-31 | $2.48 | -$4.18 | −62.75% |
| Q3 2021 | 2021-09-30 | $3.65 | -$3.44 | −48.52% |
| Q2 2021 | 2021-06-30 | $4.86 | — | — |
| Q1 2021 | 2021-03-31 | $5.90 | — | — |
| Q4 2020 | 2020-12-31 | $6.65 | $6.67 | — |
| Q3 2020 | 2020-09-30 | $7.09 | — | — |
| As of Dec 31, 2019 | 2019-12-31 | -$0.01 | — | — |
Taysha Gene Therapies book value per share trends
Over the last five fiscal years, Taysha Gene Therapies's book value per share decreased from $6.65 to $0.87, a change of -$5.79. The latest reported quarter, Q2 2026, shows $1.19.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗